San Francisco startup Composition Therapeutics is additionally focusing on an oral, at the time-day-to-day GLP-1 drug termed GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June when a mid-phase research showed normal weight loss of about 6% and it plans to start A different mid-phase demo to the end of this year—that founder and